Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy

Tan, RJ and Zhou, L and Zhou, D and Lin, L and Liu, Y (2013) Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy. PLoS ONE, 8 (11).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (2MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

Endothelin is a vasoconstricting peptide that plays a key role in vascular homeostasis, exerting its biologic effects via two receptors, the endothelin receptor A (ETA) and endothelin receptor B (ETB). Activation of ETA and ETB has opposing actions, in which hyperactive ETA is generally vasoconstrictive and pathologic. Selective ETA blockade has been shown to be beneficial in renal injuries such as diabetic nephropathy and can improve proteinuria. Atrasentan is a selective pharmacologic ETA blocker that preferentially inhibits ETA activation. In this study, we evaluated the efficacy of ETA blockade by atrasentan in ameliorating proteinuria and kidney injury in murine adriamycin nephropathy, a model of human focal segmental glomerulosclerosis. We found that ETA expression was unaltered during the course of adriamycin nephropathy. Whether initiated prior to injury in a prevention protocol (5 mg/kg/day, i.p.) or after injury onset in a therapeutic protocol (7 mg/kg or 20 mg/kg three times a week, i.p.), atrasentan did not significantly affect the initiation and progression of adriamycin-induced albuminuria (as measured by urinary albumin-to-creatinine ratios). Indices of glomerular damage were also not improved in atrasentan-treated groups, in either the prevention or therapeutic protocols. Atrasentan also failed to improve kidney function as determined by serum creatinine, histologic damage, and mRNA expression of numerous fibrosis-related genes such as collagen-I and TGF-β1. Therefore, we conclude that selective blockade of ETA by atrasentan has no effect on preventing or ameliorating proteinuria and kidney injury in adriamycin nephropathy. © 2013 Tan et al.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Tan, RJtanr@pitt.eduTANR
Zhou, L
Zhou, Dzhoudong@pitt.eduZHOUDONG
Lin, L
Liu, Yyhliu@pitt.eduYHLIU
Contributors:
ContributionContributors NameEmailPitt UsernameORCID
EditorChatziantoniou, ChristosUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Date: 12 November 2013
Date Type: Publication
Journal or Publication Title: PLoS ONE
Volume: 8
Number: 11
DOI or Unique Handle: 10.1371/journal.pone.0079963
Refereed: Yes
Date Deposited: 30 Jan 2014 17:38
Last Modified: 25 Jan 2019 22:55
URI: http://d-scholarship.pitt.edu/id/eprint/20378

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item